eHealth in Drug Discovery and Disease Research

  • Mats Sundgren
Part of the The Palgrave Macmillan IESE Business Collection book series (IESEBC)


Information technology is transforming the way healthcare is developed, delivered and documented, making available detailed information such as phenotypes and genetic data and holding the promise of making a great contribution to medical research. A part of this fast changing landscape is eHealth. eHealth is becoming increasingly important for the pharmaceutical industry, offering remarkable enhancement opportunities for the clinical research sector. Electronic health records (EHRs), interconnected through healthcare networks, have the potential to interact richly with research platforms while complying with all applicable legal, regulatory and ethical standards and policies. This chapter explores the great potential of eHealth to the field of drug discovery and development.


Business Model Drug Discovery Personalise Medicine Electronic Health Record Health Information Technology 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bunnage, M.E. (2011), “Getting pharmaceutical R&D back on target”, Nature Chemical Biology 7(6): 335–339.CrossRefGoogle Scholar
  2. CMR International (2012), Pharmaceutical Fact book 2012. ISBN: 978-0-9551411-9-5.Google Scholar
  3. Curtis, L.H., Weiner, M.G., Boudreau, D.M., Cooper, W.O., Daniel, G.W., Nair, V.P., Raebel, M.A., Beaulieu, N.U., Rosofsky, R., Woodworth, T.S. and Brown, J.S. (2012), “Design considerations, architecture, and use of the Mini-Sentinel distributed data system”, Pharmacoepidemiology and Drug Safety 21: 23–31.CrossRefGoogle Scholar
  4. DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (2003), “The price of innovation: new estimates of drug development costs”, Journal of Health Economics 22(2): 151–185.CrossRefGoogle Scholar
  5. DiMasi, J.A. (2002), “The value of improving the productivity of the drug development process faster times and better decisions”, Pharmacoeconomics 20(Suppl. 3): 1–10. “Medicine goes digital”, The Economist, 18 April 2009.CrossRefGoogle Scholar
  6. Geissb’hler, B., Safran, C., Buchan, I., Bellazzi, R., Labkoff, S., Eilenberg, K., Leeseh, A., Richardson, C., Mantasa, J., Murray, P. and DeMoor, G. (2013), “Trustworthy reuse of health data: a transnational perspective”, International journal of Medical Informatics 82:1–9A.CrossRefGoogle Scholar
  7. Goldman, M. (2012), “The innovative medicines initiative: a European response to the innovation challenge”, Clinical Pharmacology Therapeutics 91: 418–425.CrossRefGoogle Scholar
  8. Hermosilla, I., Kouskoumvekaki, I., Shublaq, N. and Lopez Alonso, V. (2013) Prospective analysis on Biomedical Informatics enabling personalised medicine, INBIOMED Vision Consortium. (Available at:
  9. Jensen, P.B., Jensen, L.J. and Brunak, S. (2012), “Mining electronic health records: towards better research applications and clinical care”, Nature Reviews Genetics 13(6): 395–405.CrossRefGoogle Scholar
  10. Kalra, D., Schmidt, A., Potts, H.W.W., Dupont D., Sundgren, M. and De Moor, G. (2011), “Case report from the EHR4CR project: a European survey on electronic health records systems for clinical research”, iHealth Connections 1(2): 108–113.Google Scholar
  11. Lehner, J-P., Epstein, R.S. and Tehseen, S. (2012), “Integrating new approaches for clinical development: translational research and relative effectiveness”, Journal of Comparative Effect Research 1(1) (Suppl. 1): 15–21.CrossRefGoogle Scholar
  12. Microsoft Research (2006), Towards Science 2020, Cambridge, UK. (Available at
  13. Olsson, M. (2011), The Data Explosion and the Future of Health: What Every Decision-Maker in the Health and Healthcare Industries Need To Know about the Coming Revolution, Kairos Future, Sweden. (Available at:
  14. Paul, S.M., Mytelka, D.S., Dunwiddie, CT., Persinger, CT., Munos, B.H., Lindborg, S.R. and Schact, A.L. (2010), “How to improve R&D productivity: the pharmaceutical industry’s grand challenge”, Nature Reviews Drug Discovery 9(3): 203–214.Google Scholar
  15. Styhre, A. and Sundgren, M. (2011), Venturing into the Bioeconomy: Professional Ideologies, Identity and Innovation. London, UK: Palgrave MacMillan. ISBN: 978-0-2302383-6-7.CrossRefGoogle Scholar
  16. Sundgren, M. (2011), “Connection power in the new information landscape”, European Pharmaceutical Contractor Quarterly June: 71–73.Google Scholar
  17. Sundgren, M., Wilson, P. and de Zegher, I. (2009), “Making the most of the Electronic Age”, European Pharmaceutical Contractor (3): 18–21.Google Scholar
  18. Zott, C., Amit, R. and Massa, L. (2010), The Business Model: Theoretical Roots, Recent Developments, and Future Research. Working Paper WP-862, IESE Business School, University of Navarra, 1–45.Google Scholar

Copyright information

© Mats Sundgren 2014

Authors and Affiliations

  • Mats Sundgren

There are no affiliations available

Personalised recommendations